Sanofi

Sanofi (赛诺菲) is the French pharma multinational; in elsewhere's corpus it shows up mainly as an active dealmaker with Chinese AI-drug-discovery companies. In 2022 it partnered with Insilico Medicine and Atomwise on AI-driven drug development , and in 2023 with BioMap to co-develop biological therapeutics models based on BioMap's life science foundation model . Its deepest tie is with Earendil Labs (华深智药): in April 2025 the two signed an exclusive global license for bispecific antibodies HXN-1002 and HXN-1003 — $125 million upfront and up to $1.72 billion in milestones — followed in 2026 by a broader strategic collaboration worth up to $2.56 billion, bringing their cumulative licensing deals to over $4.4 billion, per 高榕创投 and 五源资本 . Sanofi also joined as an investor in Earendil's $787 million round in March 2026 , and sits among the industrial LPs in Cathay Capital's third innovation fund .

Beyond that, elsewhere's corpus doesn't profile Sanofi itself — its size, history, or pipeline aren't covered.